Patents Assigned to Expression Drug Designs, LLC
  • Sphingosine 1-Phosphate Antagonism
    Publication number: 20120225064
    Abstract: Materials and Method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of sphingosine-1-phosphate receptor subtype 3 are provided.
    Type: Application
    Filed: May 14, 2012
    Publication date: September 6, 2012
    Applicant: EXPRESSION DRUG DESIGNS, LLC
    Inventors: Deron R. HERR, Greg L. HARRIS
  • Sphingosine 1-phosphate antagonism
    Patent number: 8212010
    Abstract: Materials and Method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of sphingosine-1-phosphate receptor subtype 3 are provided.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: July 3, 2012
    Assignee: Expression Drug Designs, LLC
    Inventors: Deron R. Herr, Greg L. Harris
  • SPHINGOSINE 1-PHOSPHATE ANTAGONISM
    Publication number: 20090226453
    Abstract: Materials and Method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of sphingosine-1-phosphate receptor subtype 3 are provided.
    Type: Application
    Filed: February 24, 2009
    Publication date: September 10, 2009
    Applicant: Expression Drug Designs, LLC
    Inventors: Deron R. Herr, Greg L. Harris